Abstracts tagged "osteoclastogenesis"

Abstract Number: 580 • 2016 ACR/ARHP Annual Meeting
Preferential Distribution of M1 Monocytes in Anti-Cyclic Citrullinated Peptide Antibody Positive Patients with Rheumatoid Arthritis
Shoichi Fukui¹, Naoki Iwamoto², Toshimasa Shimizu², Masataka Umeda², Ayako Nishino³, Yoshiro Horai², Tomohiro Koga⁴, Shin-ya Kawashiri⁵, Kunihiro Ichinose⁶, Yasuko Hirai², Mami Tamai⁶, Hideki Nakamura⁵, Tomoki Origuchi⁷ and Atsushi Kawakami⁴, ¹Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Department of Immunology and Rheumatology, Unit of Translational Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan, ³Department of Immunology and Rheumatology, Unit of Translational Medicine, Graduate School of Biomedical Sciences, Nagasaki Universit, Nagasaki, Japan, ⁴Unit of Advanced Preventive Medical Sciences, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁵Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁶Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁷Department of Rehabilitation Sciences, Nagasaki University, Nagasaki, Japan
Background/Purpose: In rheumatoid arthritis (RA), bone erosions are caused mainly by osteoclasts. Osteoclasts are derived from monocytes and macrophages (MoMa). MoMa consists of different subtypes…
Abstract Number: 1101 • 2016 ACR/ARHP Annual Meeting
Adalimumab:TNF Complexes Induce a Divergent Proteomic Profile in Human Osteoclast Precursors to That Resembling a Monocytic Cell
Bohdan P. Harvey¹, Chenqi Hu², Dongdong Wang², Yu Tian² and Zehra Kaymakcalan¹, ¹Global Biologics, AbbVie Bioresearch Center, Worcester, MA, ²DMPK-BA, AbbVie Bioresearch Center, Worcester, MA
Background/Purpose: TNF has been shown to contribute to osteoclastogenesis independently and in conjunction with M-CSF or RANKL, two key cytokines involved in osteoclast (OC) development.…
Abstract Number: 1156 • 2015 ACR/ARHP Annual Meeting
Th17 Cytokines Regulate Osteoclastogenesis in Rheumatoid Arthritis
MIN-YOUNG JUNG¹, Hae-Rim Kim², HYUN-SOOK KIM³, HO-YOUN KIM¹ and Sang Heon Lee⁴, ¹Konkuk university hospital, Seoul, South Korea, ²Division of Rheumatology, Konkuk University School of Medicine, Seoul, South Korea, ³Soonchenhyang university school of medicine, Seoul, South Korea, ⁴Konkuk University Hospital, Seoul, South Korea
Background/Purpose: This study aimed to determine the regulatory effect of Th17 cytokines on osteoclastogenesis in rheumatoid arthritis (RA). Methods: The expression of interleukin (IL)-17 and…
Abstract Number: 2085 • 2015 ACR/ARHP Annual Meeting
DC-STAMP Regulates Osteoclastogenesis through the Ca2+ /NFATc1 Axis
Yahui Grace Chiu¹, Dongge Li², Yue-Xin Xu³, Tzong-Ren Sheu⁴, Minsoo Kim⁵ and Christopher T. Ritchlin⁶, ¹Allergy, Immunology, and Rheumatology, University of Rochester, Rochester, NY, ²Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ³Microbiology & Immunology, University of Rochester, Rochester, NY, ⁴Center for Musculoskeletal Research, University of Rochester, Rochester, NY, ⁵Microbiology and Immunology, University of Rochester, Rochester, NY, ⁶Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Osteoclasts (OC) are the only cell type known to erode bone. Many bone diseases including osteoporosis and arthritis are caused by excessive OC activity.…
Abstract Number: 2086 • 2015 ACR/ARHP Annual Meeting
Inhibition of Macrophage Inflammatory Protein 1-Alpha (CCL3) Significantly Reduced Bone Resorption in Vitro and the Development of Erosive Joint Pathology in Collagen-Induced Arthritis
Lauren A. Jordan¹, Ruth Davies¹, Alastair J. D. Robertson², Ann K. Harvey¹, Ernest H. Choy¹, Malin Erlandsson³, Maria I. Bokarewa⁴, Rachel J. Errington¹ and Anwen S. Williams¹, ¹Cardiff University, Institute of Infection and Immunity, Tenovus Building, University Hospital of Wales, Cardiff, United Kingdom, ²William Harvey Hospital, Willesborough, Ashford, United Kingdom, ³University of Goteborg, Goteborg, Sweden, ⁴Guldhedsgatan 10, University of Goteborg, Goteborg, Sweden
Background/Purpose: The destruction of bone is a common feature of diseases like rheumatoid arthritis (RA) and multiple myeloma (MM). CCL3 is significantly elevated in the…
Abstract Number: 3170 • 2015 ACR/ARHP Annual Meeting
Peripheral Osteoblastogenesis in Rheumatoid Arthritis Is Enhanced after TNF Blocker Treatment, Irrespective of Systemic Inflammation
Mie Jin Lim¹, Won Park², Seong-Ryul Kwon², Kyong-Hee Jung² and Min Jung Son³, ¹Division of Rheumatology, Department of Internal Medicine,, Inha University Hospital, Incheon, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ³Inha University Hospital, Incheon, South Korea
Background/Purpose: We investigated osteoclastogenesis and osteoblastogenesis in peripheral blood before and 6 months after TNF blocker treatment in seropositive RA patients. Methods: Seventeen seropositive…
Abstract Number: 2794 • 2014 ACR/ARHP Annual Meeting
Deletion of the Inhibitory Receptor Motif, ITIM, on DC-STAMP Alters Osteoclast Differentiation and Function
Yahui Grace Chiu¹, Edward M. Schwarz², Dongge Li¹, Yuexin Xu³, Minsoo Kim³ and Christopher T. Ritchlin⁴, ¹Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ²Center for Musculoskeletal Research, University of Rochester, Rochester, NY, ³Microbiology and Immunology, University of Rochester, Rochester, NY, ⁴Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose DC-STAMP (Dendritic Cell-Specific Transmembrane Protein), a 7-pass transmembrane protein essential for cell-to-cell fusion during osteoclast (OC) differentiation, is expressed on the cell surface of…
Abstract Number: 1888 • 2014 ACR/ARHP Annual Meeting
PU.1, Mitf, and Their Novel Co-Partner, Eomes, Set up a Transcription Factor Network That Is Critical for Osteoclast Differentiation
Heather Carey¹, Sankha Ghosh¹, Eason Hildreth III², Jennifer Cabrera¹, Dias Kurmashev¹, Wael N. Jarjour³, Ramiro Toribio², Sudarshana Sharma¹ and Michael Ostrowski¹, ¹Molecular and Cellular Biochemistry, The Ohio State University, Columbus, OH, ²Veterinary Clinical Sciences, The Ohio State University, Columbus, OH, ³Dept of Rheumatology/Medicine, The Ohio State University Wexner Medical Center, Columbus, OH
Background/Purpose Osteoclasts are bone resorbing cells which differentiate from myeloid precursors. The crosstalk between osteoblasts and osteoclasts tightly regulates the dynamic and continuous process of…
Abstract Number: 37 • 2014 ACR/ARHP Annual Meeting
Regulation of Osteoclast and T Cell Differentiation By DC-STAMP and TRAF3
Yahui Grace Chiu¹, Jinbo Li², Dongge Li¹, Brendan Boyce² and Christopher T. Ritchlin³, ¹Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ²Pathology, University of Rochester, Rochester, NY, ³Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose DC-STAMP (Dendritic Cell-Specific Transmembrane Protein) is a 7-pass transmembrane protein essential for cell-to-cell fusion during OC differentiation. We have previously shown that DC-STAMP is…
Abstract Number: 2728 • 2013 ACR/ARHP Annual Meeting
The Small Ubiquitin Related Modifier-1 (SUMO-1) Regulates Osteoclast Differentiation In Vitro and In Vivo.
Svetlana Frank¹, Daniel Umlauf², Olli A. Jänne³ and Thomas Pap⁴, ¹Institute of Experimental Musculoskeletal Medicine, University Hospital Münster, Muenster, Germany, ²Institute of Experimental Musculoskeletal Medicine, University Hospital Muenster, Muenster, Germany, ³Univ Helsinki, Inst Biomed Physiol, Biomedicum, Helsinki, Finland, ⁴Institute of Experimental Muskuloskeletal Medicine, University Hospital Münster, Münster, Germany
Background/Purpose: Posttranslational modification of proteins by SUMO has been shown for a number of target molecules including transcription factors and is involved in a variety…
Abstract Number: 2312 • 2012 ACR/ARHP Annual Meeting
Senescent T Cells Promote Bone Loss in Rheumatoid Arthritis
Johannes Fessler¹, Rusmir Husic², Elisabeth Lerchbaum³, Verena Schwetz³, Claudia Stiegler³, Barbara Obermayer-Pietsch³, Winfried B. Graninger⁴ and Christian Dejaco⁵, ¹Rheumatology and Immunology, Medical University Graz, Graz, Austria, ²Rheumatology, Medical University Graz, Graz, Austria, ³Division of Endocrinology and Metabolism, Medical University Graz, Graz, Austria, ⁴Internal medicine/Rheumatology and Immunology, Medical University Graz, Graz, Austria, ⁵Rheumatology, Southend University Hospital, Westcliff-on-Sea, United Kingdom
Background/Purpose: To study the influence of aged CD28-T cells on systemic osteoporosis in rheumatoid arthritis (RA) patients. Methods: Prospective, cross-sectional study on 100 patients with…
Abstract Number: 36 • 2012 ACR/ARHP Annual Meeting
Role of FK506 Binding Protein 5 in Osteoclast Differentiation
Miho Kimura¹, Tatsuo Nagai², Reiko Matsushita², Atsushi Hashimoto³, Toshiyuki Miyashita⁴ and Shunsei Hirohata⁵, ¹Rheumatology and Infectious diseases, Kitasato University School of Medicine, Sagamihara, Japan, ²Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan, ³Department of Rheumatology, National Hospital Organization Sagamihara Hospital, Kanagawa, Japan, ⁴Molecular Genetics, Kitasato University School of Medicine, Sagamihara, ⁵Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan
Background/Purpose: RA is a chronic, systemic inflammatory disease characterized by the destruction of bone in the joints. Moreover, it is well appreciated that systemic osteoporosis…
Abstract Number: 14 • 2012 ACR/ARHP Annual Meeting
EPAC1 Activation Is Required for NFkB Nuclear Translocation and Osteoclast Differentiation
Aranzazu Mediero¹ and Bruce N. Cronstein², ¹Medicine, Division of Translational Medicine, NYU School of Medicine, New York, NY, ²Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose: Previous work demonstrated that one mechanism by which bisphosphonates inhibit osteoclast differentiation and function is via inhibition of Rap1A isoprenylation and, as a result,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].